Equities analysts predict that Akari Therapeutics PLC (NASDAQ:AKTX) will announce earnings per share of ($1.00) for the current quarter, according to Zacks. Zero analysts have issued estimates for Akari Therapeutics’ earnings. Akari Therapeutics reported earnings of ($0.08) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 1,150%. The firm is expected to report its next earnings results on Friday, March 30th.
On average, analysts expect that Akari Therapeutics will report full-year earnings of ($2.50) per share for the current fiscal year, with EPS estimates ranging from ($3.00) to ($2.00). For the next fiscal year, analysts expect that the firm will report earnings of ($2.00) per share, with EPS estimates ranging from ($3.00) to ($1.00). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Akari Therapeutics.
Akari Therapeutics (NASDAQ:AKTX) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.91.
Several hedge funds have recently made changes to their positions in the company. AWM Investment Company Inc. purchased a new position in shares of Akari Therapeutics in the fourth quarter valued at $2,962,000. Millennium Management LLC increased its position in shares of Akari Therapeutics by 125.0% in the fourth quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 144,477 shares in the last quarter. Finally, Hikari Power Ltd increased its position in shares of Akari Therapeutics by 152.2% in the third quarter. Hikari Power Ltd now owns 151,334 shares of the biopharmaceutical company’s stock valued at $929,000 after buying an additional 91,322 shares in the last quarter. Institutional investors and hedge funds own 21.05% of the company’s stock.
Shares of Akari Therapeutics (AKTX) opened at $2.42 on Thursday. Akari Therapeutics has a fifty-two week low of $2.06 and a fifty-two week high of $22.20. The company has a market capitalization of $30.03, a price-to-earnings ratio of -8.64 and a beta of -9.00.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.